CMS and FDA The History and Horizon of Regulatory Coordination

Slides:

Advertisements

Similar presentations

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.

Advertisements

Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process Barbara Grenell, Preferred Health Strategies.

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

Development of ISO standards for AD syringes SIGN Meeting Cambodia, October 2002 Injection technologies G Gerald Verollet.

1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.

IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:

Good Clinical Practice GCP

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

Propriety and Confidential. Do not distribute. 1 What do MCO’s need from network participants? High quality services that are also compliant with state.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

1 Cross Labeling Combination Products Bradley Merrill Thompson, MBA, JD, RAC Epstein Becker & Green PC.

1 The Role of Medicare National Coverage in the Regulatory Process Steve Phurrough MD, MPA Director, Coverage and Analysis Group Centers for Medicare and.

Chapter 5 Part III. 2 Executive Orders Regulating Rulemaking What is the president's authority over rulemaking? What about for independent agencies? Why.

© 2004 Moses & Singer LLP HIPAA and Patient Privacy Issues Raised by the New Medicare Prescription Drug Program National Medicare Prescription Drug Congress.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

Special Meeting on Procedures for Information Exchange November 7, 2007 Geneva Session 1 Anne Meininger United States USA WTO TBT Enquiry Point.

CMS and FDA’s Regulatory Review & Coverage Coordination

THE INSTITUTIONAL REVIEW BOARD. WHAT IS AN IRB? An IRB is committee set up by an institution to review, approve, and regulate research conducted under.

EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.

Clinical Trials.

1 Regulatory And Cost Containment Issues Affecting Molecular Diagnostics Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology.

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

Intersecting roles CMS and FDA – implications for pharmaceutical and device industries Peter B. Bach, MD, MAPP Senior Adviser, Office of the Administrator.

Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.

Chapter 7 Part III. Inferring Tenure What is the assumption if there is no term of office? If there is no term of office, the starting assumption is that.

European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.

Rachel Neubrander, PhD Division of Cardiovascular Devices

The CRT of EFS Where We’ve Been and Where We’re Going

Back to Basics – Approval Criteria

Update on CMS Financial Alignment Initiative and State Integration Efforts Inside and Outside Demonstration Authority Lindsay Barnette Medicare-Medicaid.

Carol Callaghan Michigan Department of Community Health and

Adherence to the Labeling

3.03 Understand support services Introduction

FDA’s IDE Decisions and Communications

Director, Asia Pacific Japan and U.S. Clinical Operations

Enrolling in Clinical Trials

Balancing Pre and Postmarket Requirements Different Scenarios

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Missouri Behavioral Health Independent Practice Association (IPA)

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

The FDA Early Feasibility Study Pilot and the Innovation Pathway

First-in-Man, First In The USA: What’s The Difference?

Regulatory Synergies in Device Innovation

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Lessons Learned: Past Present and Future Japan-USA Regulatory Interactions Erica Takai, PhD US Food and Drug Administration

US Early Feasibility Studies (EFS)

Lessons Learned Through HBD: The Regulator’s View - US FDA

Bozeman Health Clinical Research

FDA-CDRH in the Next Decade A Vision for Change

3.03 Understand support services Introduction

Boost Your Competitive Strength by Standards!

Pathways To Coverage Jim Almas, M.D. Coverage and Analysis Group (CAG)

3.03 Understand support services Introduction

International Statistical Conference: INDEC's 50th Anniversary

Streamlining IRB Procedures for Expanded Access

EDUCATE: A NESTcc Demonstration Project Regulatory Perspective

3.03 Understand support services Introduction

3.03 Understand support services Introduction

Exploring 45 CFR , Criteria for IRB Approval of Research

Optum’s Role in Mycare Ohio

3.03 Understand support services Introduction

Dr Manisha Shridhar Regional Advisor WHO-SEARO

3.03 Understand support services Introduction

Regulatory Perspective of the Use of EHRs in RCTs

EUnetHTA Assembly May 2018.

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Presentation transcript:

CMS and FDA The History and Horizon of Regulatory Coordination Louis Jacques MD, Director Coverage and Analysis Group CMS

History FDA and CMS have separate authorities and standards under statute Safe and Effective v. Reasonable and Necessary Both depend on access to robust data of clinical outcomes Coordination before 2010 has been ad hoc Product specific MOUs Sponsor-specific invitations to have joint meetings Attendance at each other’s symposia etc. CMS rep on FDA Council for Medical Device Innovation

Things we hear… FDA approved it so CMS must cover it. Just because FDA didn’t approve it…CMS should cover it anyway. We don’t think the Boxed Warning is really relevant to this indication. FDA won’t allow us to include clinical outcomes in our trial. We can’t share (our own) data with you without getting FDA approval. These post approval requirements are nothing special.

CMS and FDA: Parallel Review Parallel review is a voluntary process that allows overlapping review and evaluation of certain FDA-regulated medical products by both CMS and FDA prior to products entering the market. Purpose: Help speed consumer access to those new medical products and services that demonstrate benefit. Both agencies seek a process that allows them to share data and information collaboratively in a way that protects the confidentiality of proprietary information and safeguards patients’ privacy. Enhance administrative and regulatory efficiency.

Parallel Review How it works To occur only if a product sponsor and both agencies agree to use this process CMS action will depend on the stage of the FDA review timeline. When parallel review is utilized, CMS may launch a national coverage analysis (NCA) to determine whether the product is reasonable and necessary for the Medicare population while FDA completes its pre-market review to determine whether the product meets applicable safety and effectiveness standards. Alternatively, compelling clinical trial evidence may obviate the need for an NCA if local Medicare contractors cover it under their own authority.

Parallel Review Potential effects: Standard of review Could save time and resources as both agencies work together to review medical technologies Standard of review Proposal does not change any substantive element of FDA’s legal responsibility to ensure that technologies marketed in the United States meet applicable safety and effectiveness requirements Proposal does not change CMS’ legal responsibility to assure that technologies covered by Medicare are “reasonable and necessary” for beneficiaries

Horizon Review public comments on the FR Notice Develop and disseminate a roadmap for parallel review participants Parallel review pilot(s) Support collaboration on single manufacturer-sponsored clinical trial to meet both FDA's and CMS's evidentiary requirements

FDA CMS MOU http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm217585.htm

FDA-CMS Parallel Review FR Notice http://www.federalregister.gov/articles/2010/09/17/2010-23252/parallel-review-of-medical-products